|
|
|||||||||||||||||||||||||||||||||||||
By The Online Investor Staff, updated Wed., May. 22, 7:12 AM
|
||||||||||||||||||||||||||||||||||||||
| This Slide: #2 of 25 |
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s portfolio of products include: human immunodeficiency virus/ acquired immune deficiency syndrome, which includes Stribild®, Complera®/Eviplera®, Atripla®, Truvada®, Viread®, and Emtriva®; liver disease, which includes Viread® and Hepsera®; cardiovascular, which includes Letairis®, Ranexa®, and Lexiscan/Rapiscan®; Respiratory, which includes Cayston® and Tamiflu; and other, which includes AmBisome®, Vistide® and Macugen. Co. has operations in North America, Europe and Asia.
Open the GILD Page at The Online Investor »
|
|||||||||||||||||||||
Open the GILD Page at The Online Investor (in a new window) »
Strong Buy (3.62 out of 4) 83rd percentile
(ranked higher than approx. 83% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
Trade GILD Now: |
Strong Buy (3.62 out of 4) 83rd percentile
(ranked higher than approx. 83% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |